Geographical distribution of clinical trials in amyotrophic lateral sclerosis: a scoping review

References

• Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Euro J Neurol. 2020; 27:1918–29.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol. 2017;13:96–104.
   PubMed Web of Science ®Google Scholar
• Zufiría M, Gil-Bea FJ, Fernández-Torrón R, Poza JJ, Muñoz-Blanco JL, Rojas-García R, et al. ALS: A bucket of genes, environment, metabolism and unknown ingredients. Prog Neurobiol. 2016;142:104–29.
   PubMed Web of Science ®Google Scholar
• Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32:771–6.
   PubMed Web of Science ®Google Scholar
• Alonso A, Logroscino G, Jick SS, Hernán MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol. 2009;16:745–51.
   PubMed Web of Science ®Google Scholar
• Marin B, Boumédiene F, Logroscino G, Couratier P, Babron MC, Leutenegger AL, et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2017;46:57–74.
   PubMed Web of Science ®Google Scholar
• GBD 2016 Motor Neuron Disease Collaborators. Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:1083–97.
   PubMed Web of Science ®Google Scholar
• Shahrizaila N, Sobue G, Kuwabara S, Kim SH, Birks C, Fan DS, et al. Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. J Neurol Neurosurg Psychiatry. 2016;87:821–30.
   PubMed Web of Science ®Google Scholar
• Park J, Kim JE, Song TJ. The global burden of motor neuron disease: an analysis of the 2019 global burden of disease study. Front Neurol. 2022;13:864339.
   PubMedGoogle Scholar
• Hardiman O, Heverin M, Rooney J, Lillo P, Godoy G, Sáez D, et al. The Latin American epidemiology network for ALS (Laenals). Amyotroph Lateral Scler Frontotemporal Degener. 2022;23:372–7.
   PubMed Web of Science ®Google Scholar
• Xu L, Liu T, Liu L, Yao X, Chen L, Fan D, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020;267:944–53.
   PubMed Web of Science ®Google Scholar
• Jiang J, Wang Y, Deng M. New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022. Front Pharmacol. 2022;13:1054006.
   PubMed Web of Science ®Google Scholar
• Khamaysa M, Pradat P-F. Status of ALS treatment, insights into therapeutic challenges and dilemmas. J Pers Med 2022;12:1601.
   PubMed Web of Science ®Google Scholar
• Ketabforoush AHME, Chegini R, Barati S, Tahmasebi F, Moghisseh B, Joghataei MT, et al. Masitinib: the promising actor in the next season of the amyotrophic lateral sclerosis treatment series. Biomed Pharmacother. 2023;160:114378.
   PubMed Web of Science ®Google Scholar
• Lynch K. Optimizing pharmacologic treatment for ALS to improve outcomes and quality of life. Am J Manag Care. 2023;29:S112–S119.
   PubMed Web of Science ®Google Scholar
• Akçimen F, Lopez ER, Landers JE, Nath A, Chiò A, Chia R, et al. Amyotrophic lateral sclerosis: translating genetic discoveries into therapies. Nat Rev Genet. 2023; 24:642–58.
   PubMed Web of Science ®Google Scholar
• Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019; 13:1310.
   PubMed Web of Science ®Google Scholar
• Chia R, Chiò A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17:94–102.
   PubMed Web of Science ®Google Scholar
• Gene therapies should be for all. Nat Med 2021;27:1311.
   PubMed Web of Science ®Google Scholar
• Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467–73.
   PubMed Web of Science ®Google Scholar
• Wong C, Stavrou M, Elliott E, Gregory JM, Leigh N, Pinto AA, et al. Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun. 2021;3:fcab242.
   PubMedGoogle Scholar
• Suzuki N, Nishiyama A, Warita H, Aoki M. Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy. J Hum Genet. 2023;68:131–52.
   PubMed Web of Science ®Google Scholar
• Bonifacino T, Zerbo RA, Balbi M, Torazza C, Frumento G, Fedele E, et al. Nearly 30 years of animal models to study amyotrophic lateral sclerosis: a historical overview and future perspectives. Int J Mol Sci 2021;22:12236.
   PubMed Web of Science ®Google Scholar
• Fournier CN. Considerations for amyotrophic lateral sclerosis (ALS) clinical trial design. Neurotherapeutics. 2022;19:1180–92.
   PubMed Web of Science ®Google Scholar
• Kiernan MC, Vucic S, Talbot K, McDermott CJ, Hardiman O, Shefner JM, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17:104–18.
   PubMed Web of Science ®Google Scholar
• Berry JD, Cudkowicz ME. New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Investig (Lond). 2011;1:1375–89.
   PubMedGoogle Scholar
• van Eijk RPA, Nikolakopoulos S, Roes KCB, Kendall L, Han SS, Lavrov A, et al. Innovating clinical trials for amyotrophic lateral sclerosis: challenging the established order. Neurology 2021;97:528–36.
   PubMed Web of Science ®Google Scholar
• Informe final estado de situación la esclerosis lateral amiotrófica en América Latina y El Caribe. Noviembre 2021. Esteban Bullrich Foundation.
   Google Scholar